LinusBio, a 2021 spinoff company from Mount Sinai, announced a Series A venture capital funding to deliver a novel platform that bridges genomics, the environment, and biological response. The company’s platform is based on new methods and technology developed by scientists at the Institute for Exposomic Research at Mount Sinai.
In a new book, Dr. Manish Arora and Dr. Paul Curtin of the Mount Sinai Institute for Exposomic Research suggest that a newly proposed component—the biodynamic interface—may better explain how humans interact with their environment
StrandDx™- ASD Exposome Sequencing Diagnostic was developed based on technology developed by researchers in the Institute for Exposomic Research at Mount Sinai.
Subject to regulatory approvals, the new company intends to launch its first product with StrandDx™- ASD a molecular biomarker for autism spectrum disorder that can be applied at birth, and can assist in early Autism Spectrum Disorder diagnosis.
Mount Sinai Research Could Result in Early Diagnostic System for Autism Spectrum Disorder